Announced details
Personal health management, B2C healthcare
The impact on consolidated results for the current fiscal year is currently expected to be immaterial.
The company does not address Contract Value / Offering price.
Research literature and other sources from Japan and overseas
| Item | Details |
|---|---|
| Names of Products / Services Covered | Well-aging business, WELLMILL, Genetic age measurement kit, グルたまエイジング (well-aging supplement) |
| Launch date | 29 September 2026 (sales launch, actual) |
| Applicable area | Personal health management, B2C healthcare |
| Impact on Business Performance | The impact on consolidated results for the current fiscal year is currently expected to be immaterial. |
| Source | Research literature and other sources from Japan and overseas |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To apply knowledge of iPS cells and reprogramming technologies developed over approximately 20 years to products and services that support everyday health management, with the aim of strengthening its B2C business and creating new customer segments and revenue opportunities.